Iovance Biotherapeutics sinks following hold placed on IOV-LUN-202 trial Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Cytokinetics (CYTK) up 56% after announcing topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
- Enveric Biosciences (ENVB) up 1% after the company said the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results
- Tesla (TSLA) up 1% after Bloomberg reported Tesla is preparing to launch a revamped version of its Model Y vehicle from its Shanghai plant
- MicroStrategy (MSTR) up 1% after disclosing that, during the period between November 30 and December 26, the company acquired approximately 14,620 bitcoins for approximately $615.7M in cash
- Coherus Biosciences (CHRS) up 40% after announcing that the FDA approved Udenyca Onbody
UP AFTER EARNINGS -
LOWER -
- Iovance Biotherapeutics (IOVA) down 23% after announcing the FDA put a clinical hold on IOV-LUN-202 trial
- Consolidated Communications (CNSL) down 1% after reiterating that shareholders should vote for the proposed acquisition of the Company by affiliates of Searchlight Capital Partners and British Columbia Investment Management Corporation
Symbols:
CYTK ENVB TSLA MSTR - $603.75 /
-15.235 (-2.46%)
CHRS SWVL IOVA CNSLConsolidated Communications
Keywords: Fly Intel, Wall Street, Top Stories, Stocks